Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

by Zacks Equity Research

Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

    Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved

    by Zacks Equity Research

    Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.

      CVS Health (CVS) Q1 Earnings Beat Estimates, Decrease Y/Y

      by Zacks Equity Research

      CVS Health Corporation (CVS) reported first-quarter 2017 adjusted earnings per share (EPS) of $1.17, down 0.8% year over year.

        Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2

        by Zacks Equity Research

        Hill-Rom Holdings, Inc. (HRC) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 88 cents, up 23.9% from the year-ago quarter.

          Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

          by Zacks Equity Research

          Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

            AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates

            by Zacks Equity Research

            AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.

              Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss

              by Zacks Equity Research

              Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.

                Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates

                by Zacks Equity Research

                Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.

                  Align Technology (ALGN) Beats on Q1 Earnings and Revenues

                  by Zacks Equity Research

                  Align Technology Inc. (ALGN) reported adjusted earnings per share (EPS) of 85 cents in the first quarter of 2017, up 70% from 50 cents posted in the year-ago quarter.

                    Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

                    by Zacks Equity Research

                    Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

                      Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

                      by Zacks Equity Research

                      Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.

                        AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y

                        by Zacks Equity Research

                        AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.

                          Bayer (BAYRY) Beats Q1 Earnings, Revenue Estimates

                          by Zacks Equity Research

                          Bayer AG's (BAYRY) first-quarter 2017 core earnings per share from continuing operations was $2.80 which beat the Zacks Consensus Estimate of $2.40.

                            Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View

                            by Zacks Equity Research

                            Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.

                              The Medicines Company (MDCO) Q1 Loss Wider Than Expected

                              by Zacks Equity Research

                              The Medicines Company (MDCO) reported loss $1.44 per share, wider than the Zacks Consensus Estimate of a loss of $1.13.

                                Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1

                                by Zacks Equity Research

                                Chemed Corp.'s (CHE) first-quarter 2017 adjusted earnings per share (EPS) (considering stock-based compensation expense and related tax benefit as a regular one) were $1.92, as compared to the year-ago adjusted EPS figure of $1.52, up 26.3% year over year.

                                  CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

                                  by Zacks Equity Research

                                  CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).

                                    Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne

                                    by Zacks Equity Research

                                    Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne

                                      Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

                                      by Zacks Equity Research

                                      Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).

                                        Arena Pharma (ARNA) Down After Underwritten Public Offering

                                        by Zacks Equity Research

                                        Arena Pharmaceuticals, Inc.'s (ARNA) shares dropped more than 13% on Apr 18, after the company announced that it will be raising funds through an underwritten public offering.

                                          Tirthankar Chakraborty headshot

                                          Create an Efficient Portfolio with 5 Top Stocks

                                          by Tirthankar Chakraborty

                                          Price performance is believed to be positively correlated with efficiency level.

                                            Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

                                            by Zacks Equity Research

                                            Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

                                              Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug

                                              by Zacks Equity Research

                                              Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).

                                                Roche's Hemophilia A Drug Positive in Second Phase III Study

                                                by Zacks Equity Research

                                                Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

                                                  Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.

                                                  by Zacks Equity Research

                                                  Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.